Order
Now

Your partner in dilation reversal

The only commercially available
FDA-approved product that reverses pharmacologically-induced mydriasis.1

RYZUMVI® is the first and only relatively non-selective alpha-1 and alpha-2 adrenergic antagonist approved to reverse pharmacologically-induced mydriasis.1

RYZUMVI reversibly binds to alpha-1 adrenergic receptors on the radial iris dilator muscle, thereby reducing pupil diameter, and indirectly reverses mydriasis induced by muscarinic antagonist effects on the iris sphincter muscle.1

The onset of action after administration of RYZUMVI generally occurs in 30 minutes, with the maximal effect seen in 60 to 90 minutes, and the effect lasting at least 24 hours.1

Redefine the patient experience post-dilation
PATIENT DILATION CHALLENGES
ABOUT RYZUMVI
EFFICACY & SAFETY
DOSING & ADMINISTRATION
ORDER RYZUMVI
REQUEST A REP

Order RYZUMVI today

Select from these
Authorized Distributors:

RYZUMVI (phentolamine ophthalmic solution) 0.75% packshot and vials

With RYZUMVI, you may be able to offer faster eye dilation reversal, helping to address patient concerns and potentially improve their post-dilation experience.1*

With
RYZUMVI—dilation may not need to disrupt your patient's entire day.1-3

*The onset of action after administration of RYZUMVI generally occurs in 30 minutes, with the maximal effect seen in 60 to 90 minutes, and the effect lasting at least 24 hours.

PATIENT DILATION
CHALLENGES

Ready to discuss your needs with Viatris?

Fill in our request form and a representative will contact you soon.

All fields required

Please enter your first name
Please enter your last name
Please enter your email address Please enter valid email address
Please enter your phone number
Please enter your office zip code
Please select your Specialty
Please enter your npi

By clicking “Submit,” you confirm that you are a US healthcare professional and agree to be contacted by a representative of Viatris. In addition, you agree to receive information about Viatris, including information about any of its current or future products or product candidates or disease state information, and you acknowledge that you have read and agree to Viatris' Privacy Policy and Terms of Use. All personal information will be kept confidential and will not be shared with any parties other than Viatris and its business partners.

Thank you

We'll be in touch!

Error

INDICATIONS AND USAGE

RYZUMVI® (phentolamine ophthalmic solution) 0.75% is indicated for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.

See full ISI

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).

Potential for Eye Injury or Contamination: To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.

Use with Contact Lenses: Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.

Adverse Reactions

The most common adverse reactions that have been reported are instillation site discomfort (16%), conjunctival hyperemia (12%), and dysgeusia (6%).

Please see Full Prescribing Information

References: 1. RYZUMVI (phentolamine ophthalmic solution). Prescribing Information. Ocuphire. 2. Goel S, Maharajan P, Chua C, Dong B, Butcher M, Bagga P. Driving ability after pupillary dilatation. Eye (Lond). 2003;17(6):735-738. 3. Siderov J, Bartlett JR, Madigan CJ. Pupillary dilation: the patient's perspective. Clin Exp Optom. 1996;79(2):62-66.